Aims: Hypoglycaemia is the major limiting factor in achieving optimal glycaemic control in people with type 1 diabetes (T1DM), especially intensively treated patients with impaired glucose counter-regulation during hypoglycaemia. Naloxone, an opiate receptor blocker, has been reported to enhance the acute counter-regulatory response to hypoglycaemia when administered intravenously in humans. The current study was undertaken to investigate the oral formulation of the long-acting opiate antagonist, naltrexone, and determine if it could have a similar effect, and thus might be useful therapeutically in treatment of T1DM patients with a high risk of hypoglycaemia.
| INTRODUCTION
The Diabetes and Complications Trial (DCCT) confirmed the longterm benefits of tight glycaemic control and this remains the therapeutic goal for patients with type 1 diabetes (T1DM). 1 However, intensive insulin regimens increase the risk of recurrent hypoglycaemia, which commonly induces a diminished ability to recognize hypoglycaemia (hypoglycaemia unawareness) and an impairment in the patient's hormonal counter-regulatory response, a phenomenon known as hypoglycaemia-associated autonomic failure (HAAF). 2 The development of HAAF occurs in approximately 20% of patients with # S. Naik and R. Belfort-DeAguiar contributed equally to this manuscript, and share first authorship.
T1DM and is a major limitation for the clinical implementation of intensive insulin treatment in T1DM. 3, 4 Indeed, severe hypoglycaemia is a significant cause of morbidity, as well as mortality, in T1DM
patients. 5, 6 Thus, there is an urgent need to develop new safe strategies for prevention and treatment of hypoglycaemia unawareness.
Recent research in this area has focused on changes in insulin preparations and insulin delivery, as well as development of closed-loop systems to diminish hypoglycaemia risk, in order to reverse or prevent the development of HAAF. [7] [8] [9] However, pharmacological treatments with beta2-agonists and opioid antagonists have also been tested for prevention and treatment of hypoglycaemia. [10] [11] [12] [13] Nakao et al. 14 reported that plasma beta-endorphins are released in response to insulin-induced hypoglycaemia. Subsequent studies found that an intravenous infusion of naloxone, an opiate receptor blocker, enhanced the counter-regulatory hormone response to hypoglycaemia in dogs, 15 as well as in healthy non-diabetic humans and in patients with T1DM. 10 More recently, the impact of the opioid system on recurrent hypoglycaemia was further investigated in healthy volunteers 16 and in patients with T1DM. 17 In the later study, naloxone was reported to ameliorate HAAF by improving counterregulatory hormonal responses. Naloxone, however, can be given only subcutaneously or intravenously, limiting its therapeutic use in an outpatient setting.
In contrast, naltrexone (unlike naloxone) is an oral opioid antagonist approved for treatment of opioid and alcohol dependence. 18 Thus, the aim of this study was to evaluate the oral formulation of naltrexone, a long acting opiate antagonist, and determine whether it will enhance the counter-regulatory response to hypoglycaemia in intensively insulin-treated patients with type 1 diabetes.
| MATERIALS AND METHODS
The study was a randomized, placebo-controlled, double-blinded, cross-over study. Nine intensively treated T1DM patients (7 male and   2 female) 18 Hepatotoxicity has been reported with doses greater than 300 mg per day. 22 The protocol was approved by the Yale University Institutional Review Board (Human Investigation Committee). All subjects provided written informed consent prior to enroling in the study. This clinical trial was registered at ClinicalTrials.gov.
| Hyperinsulinaemic euglycaemic-hypoglycaemic clamp
Prior to the clamp study, baseline blood samples were obtained for glucose and counter-regulatory hormone (epinephrine, norepinephrine, glucagon, growth hormone and cortisol) measurements. At time
Hyperinsulinaemic euglycaemic-hypoglycaemic clamp study design.
"zero," an intravenous continuous insulin infusion was started at a rate of 2 mU.kg
.min −1 and 20% dextrose was started and adjusted, based on plasma glucose levels to maintain glucose levels within the euglycaemic range (95-100 mg/dL) for 60 minutes. Subsequently, plasma glucose levels were allowed to fall and were then maintained in the hypoglycaemic range (50-55 mg/dL) for 60 minutes. Plasma insulin and counter-regulatory hormone levels were obtained throughout the entire study. 
| Biochemical analysis

| Statistical methods
All values represent the mean AE SE. A 2-way repeated measures analysis of variance (ANOVA) was performed to identify the interaction effect of treatment over time within each group, followed by post hoc analysis. Comparisons within subjects were determined by a 2-tailed Student t test for paired samples; and between subjects by unpaired Student t test for equality of means. A value of P < .05 was considered statistically significant. Graphpad Prism 4.0 software (San Diego, CA) was used for analysis.
| RESULTS
Each of the intensively treated T1DM patients was studied on 2 separate occasions. Fasting plasma glucose levels at baseline (Naltrexone:
142 AE 6 mg/dL vs placebo: 148 AE 10 mg/dL; P = NS) as well as during euglycaemia (Naltrexone: 90 AE 4 mg/dL vs placebo: 101 AE 6 mg/ dL; P = NS) and the hypoglycaemia study phase (Naltrexone:
53 AE 3 mg/dL vs placebo: 53 AE 2 mg/dL; P = NS) were not significantly different during the naltrexone and placebo sessions ( Figure 2A) . Similarly, insulin concentrations at baseline and during the hypoglycaemia clamp procedure were identical between treatment groups ( Figure 2B ). The glucose infusion rate (GIR) during the entire study, and separately, during each of the specific glucose target phases, was not significantly different in both study sessions ( Figure 2C ).
At baseline, prior to insulin infusion, there were no differences in measured hormone levels (glucagon, epinephrine, norepinephrine, cortisol and growth hormone) ( Table 1) . Evaluation of the effect of treatment with naltrexone vs placebo on counter-regulatory hormonal responses for glucagon, norepinephrine, cortisol and growth hormone during hypoglycaemia showed no treatment by time FIGURE 2 Plasma glucose (A) and insulin (B) concentrations and glucose infusion rate (GIR) (C) during the hyperinsulinaemic euglycaemichypoglycaemic clamp in subjects with type 1 diabetes after receiving naltrexone or placebo. Black circle, naltrexone; grey square, placebo. Data are presented as mean AE SE.
interaction effect in the T1DM subjects (2-way repeated measures ANOVA, P = NS) ( Table 1 and Figure 3) . However, the epinephrine response to hypoglycaemia was significantly increased between the 2 treatment groups (2-way repeated measures ANOVA; P = .05) during the hypoglycaemic phase of the hyperinsulinaemic clamp. The area under the curve for epinephrine response was 2-fold higher (P < .05) during the naltrexone study ( Figure 3) . A similar trend was observed for the GH response (Naltrexone, 2033 AE 485 vs Placebo, 936 AE 430 ng/mL; P = .061), but not for the other hormones (P = NS).
Concerning side effects, no serious adverse events were noted during or immediately after these studies. In the naltrexone group, 3 participants reported feeling nauseated, and 1 in the placebo group reported feeling nauseated. In the naltrexone group, 1 participant reported insomnia.
| DISCUSSION
Release of endogenous opioids from the anterior pituitary into the peripheral circulation is a prominent response to hypoglycaemia, 14 but its role biologically in glucose recovery remains uncertain. In the brain, opioid receptors are present in glucose-sensing regions 23 and infusion of beta-endorphin into hypothalamus has been reported to inhibit corticotropin-releasing factor secretion during hypoglycaemia. 24 Furthermore, it has been suggested that local release of betaendorphins into the ventromedial hypothalamus (VMH), a key brain glucose-sensing region during hypoglycaemia, is responsible for blunting the catecholamine response, as well as the subsequent development of counter-regulatory failure. 25 This view is supported by animal studies, demonstrating that a maladaptive VMH molecular response to hypoglycaemia can be prevented by naloxone, 26 an agent with a short half-life that is not present in an oral formulation.
This proof-of-concept study was, therefore, undertaken to determine the effect of naltrexone, a clinically available long-acting opioid antagonist, on hypoglycaemia defense mechanisms in intensively-treated T1DM patients. We observed that pre-treatment with naltrexone, given orally prior to an acute episode of hypoglycaemia, did not reduce the GIR needed to maintain glucose levels at target during a hyperinsulinaemic hypoglycaemic clamp and only modestly enhanced the epinephrine response to hypoglycaemia.
Other counteraregulatory hormones, including glucagon and norepinephrine were not significantly affected. These results are in marked contrast to previous studies using intravenous naloxone, but are consistent with a recent naltrexone study reported by Moheet et al. 13 In that study, naltrexone given for 4 weeks did not affect the frequency of hypoglycaemia, the hypoglycaemia symptoms score or counter-regulatory hormonal responses during a hypoglycaemicclamp, in contrast to previous studies using naloxone. 10, 16, 17 The discrepancy in the counter-regulatory response to hypoglycaemia between naltrexone and naloxone may be explained, in part, by differences in their mode of delivery or capacity to bind to specific opioid receptors. Beta-endorphins administered centrally in conscious dogs produce increases in circulating glucose because of a marked increase in catecholamines, 27 whereas peripheral infusion has been reported to reduce glucose production, possibly through a direct effect on the liver. 28 Naltrexone, much like naloxone, is an antagonist of the μ-, δ-, κ-opioid receptors; however, it has the highest affinity for the μ-and κ-receptors, whereas naloxone has a higher affinity for μ-and δ-receptors. 29 Naltrexone binds in a dosedependent manner to the opioid receptors with initial blockade of the μ-receptor, followed by the δ-and κ-opioid receptors, respectively. 30 Positron emission tomography scanning showed that 50 mg of naltrexone blocked 95% of the μ receptors, but only 21% of the δ-receptors in the brain. 31 This selective binding for specific opioid receptors may explain the disparity in results between these different pharmacological agents.
It should be noted that we cannot exclude that some of the discrepancies between prior naloxone studies and the current naltrexone study could relate to differences in the population studied. 10 Our subjects had a history of frequent episodes of hypoglycaemia and, thus, we cannot exclude that antecedent hypoglycaemia episodes prior to the study visit could have affected our results. One of the limitations of this study is that hypoglycaemia awareness scores were not obtained at baseline from our study participants, which could have helped identify a subgroup of patients who might have benefited from naltrexone treatment. In addition, hypoglycaemia symptom scores
were not obtained during the clamp study and, thus, we were not able to determine if naltrexone could augment the hypoglycaemic symptom score. Finally, it is possible that the period of administration Data are mean AE SE. Baseline represents the average hormonal level at −20 and 0, euglycemia represents the hormone levels at the end of the euglycemia phase (60 minutes) and hypoglycemia represents the hormone levels during hypoglycemia (average 105-150 minutes) of the 2-step euglycemic-hypoglycemic hyperinsulinemic clamp.
(12 hours) was insufficient to see an effect. However, a different treatment strategy with a month-long treatment with this same medication showed similar results. 13 Both studies used similar doses of naltrexone, those recommended for its primary treatment indication, ie, substance abuse. It is possible that a higher dose of naltrexone might be needed, as we observed a modest increase in epinephrine with this agent during hypoglycaemia. On the other hand, this possibility may be limited by its known side-effects, such as nausea and liver toxicity.
In summary, oral administration of the opioid antagonist naltrexone to T1DM patients prior to a hypoglycaemic clamp did not significantly enhance their capacity to defend against hypoglycaemia.
However, a modest increase in plasma epinephrine occurred, suggesting the potential utility of this therapeutic approach, with the development of more specific opioid receptor antagonists with different pharmacological properties and/or more potent formulations. 
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